

# Giuseppe Capri

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9221031/publications.pdf>

Version: 2024-02-01

29  
papers

1,178  
citations

361413

20  
h-index

477307

29  
g-index

29  
all docs

29  
docs citations

29  
times ranked

1437  
citing authors

#	ARTICLE	IF	CITATIONS
1	Oncological safety of selective axillary dissection after axillary reverse mapping in node-positive breast cancer. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1606-1610.	1.0	7
2	Evaluation of Local Oncologic Safety in Nipple–Areola Complex-sparing Mastectomy After Primary Chemotherapy: A Propensity Score-matched Study. <i>Clinical Breast Cancer</i> , 2017, 17, 219-231.	2.4	28
3	Pitfalls in oncology: a unique case of thoracic splenosis mimicking malignancy in a patient with resected breast cancer. <i>Journal of Thoracic Disease</i> , 2016, 8, E403-E407.	1.4	3
4	Management of breast cancer after Hodgkin’s lymphoma and paediatric cancer. <i>European Journal of Cancer</i> , 2015, 51, 1667-1674.	2.8	8
5	Axillary lymph node dissection versus no dissection in patients with T1N0 breast cancer: A randomized clinical trial (INT09/98). <i>Cancer</i> , 2014, 120, 885-893.	4.1	68
6	Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2014, 32, 1188-1196.	2.6	20
7	An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer. <i>Annals of Oncology</i> , 2010, 21, 474-480.	1.2	75
8	Phase IB Study of the mTOR Inhibitor Ridaforolimus With Capecitabine. <i>Journal of Clinical Oncology</i> , 2010, 28, 4554-4561.	1.6	47
9	Clinical and pharmacological phase I evaluation of Exherin, (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing solid tumours. <i>Annals of Oncology</i> , 2009, 20, 741-745.	1.2	63
10	Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer. <i>European Journal of Cancer</i> , 2009, 45, 1153-1161.	2.8	53
11	Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours. <i>European Journal of Cancer</i> , 2009, 45, 2116-2122.	2.8	34
12	Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours. <i>European Journal of Cancer</i> , 2008, 44, 1829-1834.	2.8	31
13	Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors. <i>Annals of Oncology</i> , 2007, 18, 561-568.	1.2	22
14	Phase I clinical study of the novel epothilone B analogue BMS-310705 given on a weekly schedule. <i>Annals of Oncology</i> , 2007, 18, 1548-1553.	1.2	36
15	Electrophysiological evaluation of visual pathways in paclitaxel-treated patients. <i>Journal of Neuro-Oncology</i> , 2006, 77, 79-87.	2.9	32
16	Visual electrophysiological evaluation in paclitaxel-treated patients. Pathophysiological mechanisms involved in retinal and optic nerve dysfunctions. <i>International Congress Series</i> , 2005, 1278, 37-40.	0.2	5
17	Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine. <i>European Journal of Cancer</i> , 2005, 41, 1746-1750.	2.8	138
18	A randomized phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as first-line chemotherapy for women with metastatic breast cancer. <i>Annals of Oncology</i> , 2004, 15, 433-439.	1.2	34

#	ARTICLE	IF	CITATIONS
19	Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin. <i>European Journal of Cancer</i> , 2004, 40, 563-570.	2.8	13
20	Cardiotoxic effects of anthracycline-taxane combinations. <i>Expert Opinion on Drug Safety</i> , 2003, 2, 59-71.	2.4	21
21	Clinical and Pharmacologic Study of the Epirubicin and Paclitaxel Combination in Women With Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2001, 19, 2222-2231.	1.6	38
22	Adjuvant and neoadjuvant treatment of breast cancer. <i>Seminars in Oncology</i> , 2001, 28, 13-29.	2.2	9
23	Clinical and pharmacological phase I study with accelerated titration design of a daily times five schedule of BBR3464, a novel cationic triplatinum complex. <i>Annals of Oncology</i> , 2000, 11, 977-984.	1.2	66
24	Treatment of AL Amyloidosis with 4-iodo-4-deoxydoxorubicin: An Update. <i>Blood</i> , 1999, 93, 1112-1113.	1.4	41
25	Scintigraphic imaging and turnover studies with iodine-131 labelled serum amyloid P component in systemic amyloidosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1998, 25, 701-708.	6.4	45
26	Biweekly paclitaxel and cisplatin in patients with advanced head and neck carcinoma. <i>Annals of Oncology</i> , 1997, 8, 1157-1158.	1.2	11
27	Paclitaxel in Metastatic Breast Cancer: a Trial of Two Doses by a 3-Hour Infusion in Patients With Dith Disease Recurrence After Prior Therapy With Anthracyclines. <i>Journal of the National Cancer Institute</i> , 1995, 87, 1169-1175.	6.3	136
28	Case Report: Technetium-99M-Hexakis-2-Methoxy-Isobutyl-Isonitrile Imaging of Breast Cancer and Myocardial Infarction in the Same Patient. <i>Tumori</i> , 1994, 80, 480-481.	1.1	5
29	Optic Nerve Disturbances: a New Form of Paclitaxel Neurotoxicity. <i>Journal of the National Cancer Institute</i> , 1994, 86, 1099-1101.	6.3	89